1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Year: 2021
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Louisville, Melanoma Institute Australia, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University Hospital Zurich, Roswell Park Comprehensive Cancer Center, University of Vienna, Medical University of Vienna, University of Chicago, Medizinische Hochschule Hannover, The Maria Sklodowska-Curie National Research Institute of Oncology, Russian Cancer Research Center NN Blokhin, University Hospital Kralovske Vinohrady, Yonsei University, Severance Hospital, European Institute of Oncology, Merck & Co., Inc., Rahway, NJ, USA (United States), Amgen (United States), Dana-Farber Cancer Institute, National and Kapodistrian University of Athens
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Amgen
OpenAlex ID: W3203855951